- The P-II study involves assessing AKCEA-ANGPTL3-LRx (SC, 40-80mg) vs PBO in 105 patients with hypertriglyceridemia, T2D, and NAFLD for 6mos.
- The P-II study resulted in meeting its primary & multiple secondary endpoints with a reduction in fasting triglycerides, ANGPTL3, apoC-III, VLDL-C, non-HDL cholesterol, no reduction in liver fat and is well tolerated
- AKCEA-ANGPTL3-LRx is an investigational antisense therapy, designed to reduce the production of ANGPTL3. Additionally, in 2019, Akcea signed a WW exclusive license agreement with Pfizer for the therapy under which Pfizer is responsible for all development and regulatory activities and costs beyond those associated with P-II study
Click here to read full press release/ article | Ref: Akcea | Image: Akcea